As alternative mTOR pathways may sustain cancer cell survival in the presence of alpelisib and PI3Kα inhibition34–36, we examined whether concurrent mTOR inhibition potentiates alpelisib mediated inhibitory effects. Here, MTOR is linked to cancer.